• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Opinion

Video

Fostering Communication: Promoting Dialogue on Atopic Dermatitis Treatment Concerns in Patients of Childbearing Potential

Author(s):

Elizabeth Kiracofe, MD, FAAD,Jenny Murase, MD, FAAD

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
Related Content
Dupilumab in Hyper-IgE Syndrome: A Case Series of Pediatric Patients
October 18th 2024

Dupilumab in Hyper-IgE Syndrome: A Case Series of Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP
October 9th 2024

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas
October 7th 2024

Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas

Q+A: Roflumilast cream 0.15% for AD with Eric Simpson, MD, MCR, FAAD
October 4th 2024

Q+A: Roflumilast cream 0.15% for AD with Eric Simpson, MD, MCR, FAAD

© 2024 MJH Life Sciences

All rights reserved.